Iso­mor­phic Labs, Al­pha­bet’s close­ly watched AI start­up, has signed its first phar­ma part­ner­ships, and will work with Eli Lil­ly and No­var­tis in deals that could be worth $3 bil­lion, CEO Demis Has­s­abis ex­clu­sive­ly told End­points News. Since its found­ing in No­vem­ber 2021, Iso­mor­phic has quick­ly be­come a lead­ing fig­ure in the fast-grow­ing AI biotech space. The Al­pha­bet sub­sidiary is ap­ply­ing Google Deep­Mind’s bi­ol­o­gy re­search — par­tic­u­lar­ly its pro­tein-str...